Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Jewell, Britta L ^a   Cremin, Ide ^a   Pickles, Michael ^a   Celum, Connie ^b   Baeten, Jared M ^b   Delany Moretlwe, Sinead ^c   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION PREVENTION; MALE; PREVALENCE; QUALITY OF LIFE; SOUTH AFRICA; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; FAMILY SIZE; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MARITAL THERAPY; PRE-EXPOSURE PROPHYLAXIS;

HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; COUPLES THERAPY; FAMILY CHARACTERISTICS; FEMALE; HIV SEROPOSITIVITY; HIV SEROPREVALENCE; HIV-1; HIV-2; HUMANS; MALE; ORGANOPHOSPHONATES; PRE-EXPOSURE PROPHYLAXIS; SOUTH AFRICA; TENOFOVIR;

EID: 84921790656     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115511     Document Type: Article

References (54)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174. doi: 10.1126/science.1193748 PMID: 20643915
2. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434. doi: 10. 1056/NEJMoa1110711 PMID: 22784038
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599. doi: 10.1056/ NEJMoa1011205 PMID: 21091279
4. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410. doi: 10.1056/ NEJMoa1108524 PMID: 22784037
5. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381: 2083-2090. doi: 10.1016/S0140-6736(13)61127-7 PMID: 23769234
6. Celum C, Morrow R, Donnell D, Hong T, Fife KH, et al. (2013) Daily Oral Tenofovir and Emtricitabine/ Tenofovir Pre-exposure Prophylaxis and Prevention of Herpes Simplex virus Type 2 Acquisition among Heterosexual Men and Women. In: 185 S, editor. Atlanta, Georgia. doi: 10.1002/jmri.24478 PMID: 25553206
7. Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, et al. (2014) Daily oral tenofovir and emtricita-bine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med 161: 11-19. doi: 10.7326/M13-2471 PMID: 24979446
8. Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, et al. (2012) HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep 9: 160-170. doi: 10.1007/s11904-012-0114-z PMID: 22415473
9. Holmberg SD, Stewart JA, Gerber AR, Byers RH, Lee FK, et al. (1988) Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 259: 1048-1050. PMID: 2828700
10. Corey L, Wald A, Celum CL, Quinn TC (2004) The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 35: 435-445. PMID: 15021308
11. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20: 73-83. PMID: 16327322
12. Corey L (2007) Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 356: 854-856. PMID: 17314346
13. Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, et al. (1999) Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect 75: 98-102. PMID: 10448361
14. Glynn JR, Biraro S, Weiss HA (2009) Herpes simplex virus type 2: a key role in HIV incidence. AIDS 23: 1595-1598. doi: 10.1097/QAD.0b013e32832e15e8 PMID: 19512858
15. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, et al. (2004) Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350: 11-20. PMID: 14702423
16. Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, et al. (2013) Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 208: 1366-1374. doi: 10.1093/infdis/jit333 PMID: 23901094
17. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43. doi: 10.1056/NEJMoa1103151 PMID: 22216840
18. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, et al. (1991) Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 324: 1247-1252. PMID: 1849612
19. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123. doi: 10.1371/journal.pmed.1001123 PMID: 22110407
20. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 362: 427-439. doi: 10.1056/ NEJMoa0904849 PMID: 20089951
21. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, et al. (2006) Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 20: 2305-2313. PMID: 17117016
22. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, et al. (2009) Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One 4: e5272. doi: 10.1371/journal.pone.0005272 PMID: 19404392
23. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, et al. (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197-2223. doi: 10.1016/S0140-6736(12)61689-4 PMID: 23245608
24. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, et al. (2009) The burden of disease and injury in Iran 2003. Popul Health Metr 7: 9. doi: 10.1186/1478-7954-7-9 PMID: 19527516
25. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, et al. (2012) Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4: 151ra125. PMID: 22972843
26. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, et al. (2013) Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Med 10: e1001511. doi: 10.1371/journal.pmed.1001511 PMID: 24058300
27. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, et al. (2014) HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. J Acquir Immune Defic Syndr.
28. World Health Organization CHOosing Interventions that are Cost Effective (WHO-CHOICE).
29. Smith JS, Robinson NJ (2002) Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186 Suppl 1: S3-28.
30. Abdool Karim Q, Kharsany AB, Leask K, Ntombela F, Humphries H, et al. (2014) Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey. Sex Transm Infect.
31. Muiru AN, Guthrie BL, Bosire R, Merkel M, Liu AY, et al. (2013) Incident HSV-2 infections are common among HIV-1-discordant couples. J Infect Dis 208: 1093-1101. doi: 10.1093/infdis/jit303 PMID: 23840044
32. Karim SS, Karim QA (2010) Effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Abstract TUSS0204 presented at the XVIII International AIDS Conference. Vienna, Austria.
33. Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, et al. (2014) Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis 14: 14. doi: 10.1186/1471-2334-14-14 PMID: 24405719
34. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098. doi: 10. 1016/S0140-6736(10)60705-2 PMID: 20537376
35. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi: 10.1056/NEJMoa1105243 PMID: 21767103
36. Heffron R, Ngure K, Mugo N, Celum C, Kurth A, et al. (2012) Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr 61: 116-119. doi: 10.1097/QAI.0b013e31825da73f PMID: 22595872
37. Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, et al. (2008) Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One 3: e1411. doi: 10.1371/journal.pone.0001411 PMID: 18183292
38. Wandel S, Egger M, Rangsin R, Nelson KE, Costello C, et al. (2008) Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 84 Suppl 1: i31-i36.
39. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826. doi: 10.1056/ NEJMoa0807252 PMID: 19339714
40. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189. PMID: 16691070
41. Mahy M, Lewden C, Brinkhof MW, Dabis F, Tassie JM, et al. (2010) Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex Transm Infect 86 Suppl 2: ii28-34. doi: 10.1136/sti.2010.044255 PMID: 21106512
42. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793. PMID: 16905784
43. Benedetti J, Corey L, Ashley R (1994) Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 121: 847-854. PMID: 7978697
44. Benedetti JK, Zeh J, Corey L (1999) Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 131: 14-20. PMID: 10391810
45. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, et al. (2001) Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149-1153. PMID: 11323041
46. Phipps W, Saracino M, Magaret A, Selke S, Remington M, et al. (2011) Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. J Infect Dis 203: 180-187. doi: 10.1093/ infdis/jiq035 PMID: 21288817
47. Augenbraun M, Feldman J, Chirgwin K, Zenilman J, Clarke L, et al. (1995) Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 123: 845-847. PMID: 7486467
48. Holmes KK, Levine R, Weaver M (2004) Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 82: 454-461. PMID: 15356939
49. Weiss HA, Halperin D, Bailey RC, Hayes RJ, Schmid G, et al. (2008) Male circumcision for HIV prevention: from evidence to action? AIDS 22: 567-574. doi: 10.1097/QAD.0b013e3282f3f406 PMID: 18316997
50. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, et al. (2009) Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 360: 1298-1309. doi: 10.1056/ NEJMoa0802556 PMID: 19321868
51. Schiffer JT, Corey L (2009) New concepts in understanding genital herpes. Curr Infect Dis Rep 11: 457-464. PMID: 19857385
52. Menzies NA, Berruti AA, Blandford JM (2012) The determinants of HIV treatment costs in resource limited settings. PLoS One 7: e48726. doi: 10.1371/journal.pone.0048726 PMID: 23144946
53. World Health Organization (2011) Global HIV/AIDS response: epidemic update and health sector progress towards Universal Access. Geneva, Switzerland. doi: 10.1080/17437199.2011.587961 PMID: 25473706
54. Gomez G, Borquez A, Case KK, Wheelock A, Vassall A, et al. (2013) The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention. PLoS Med 10: e1001401. doi: 10.1371/journal. pmed.1001401 PMID: 23554579